Literature DB >> 11577082

Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor.

S Anant1, J O Henderson, D Mukhopadhyay, N Navaratnam, S Kennedy, J Min, N O Davidson.   

Abstract

Mammalian apolipoprotein B (apoB) mRNA editing is mediated by a multicomponent holoenzyme containing apobec-1 and ACF. We have now identified CUGBP2, a 54-kDa RNA-binding protein, as a component of this holoenzyme. CUGBP2 and ACF co-fractionate in bovine liver S-100 extracts, and addition of recombinant apobec-1 leads to assembly of a holoenzyme. Immunodepletion of CUGBP2 co-precipitates ACF, and these proteins co-localize the nucleus of transfected cells, suggesting that CUGBP2 and ACF are bound in vivo. CUGBP2 binds apoB RNA, specifically an AU-rich sequence located immediately upstream of the edited cytidine. ApoB RNA from McA cells, bound to CUGBP2, was more extensively edited than the unbound fraction. However, addition of recombinant CUGBP2 to a reconstituted system demonstrated a dose-dependent inhibition of C to U RNA editing, which was rescued with either apobec-1 or ACF. Antisense CUGBP2 knockout increased endogenous apoB RNA editing, whereas antisense knockout of either apobec-1 or ACF expression eliminated apoB RNA editing, establishing the absolute requirement of these components of the core enzyme. These data suggest that CUGBP2 plays a role in apoB mRNA editing by forming a regulatory complex with the three components of the minimal editing enzyme, apobec-1, ACF, and apoB RNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577082     DOI: 10.1074/jbc.M104911200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  The challenge of target sequence specificity in C-->U RNA editing.

Authors:  Nicholas O Davidson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Co-opting endogenous microRNAs for therapy.

Authors:  Christopher E Pearson
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

3.  Natural variation in Arabidopsis leads to the identification of REME1, a pentatricopeptide repeat-DYW protein controlling the editing of mitochondrial transcripts.

Authors:  Stéphane Bentolila; Walter Knight; Maureen Hanson
Journal:  Plant Physiol       Date:  2010-10-25       Impact factor: 8.340

Review 4.  RNA surveillance: molecular approaches in transcript quality control and their implications in clinical diseases.

Authors:  Karen C M Moraes
Journal:  Mol Med       Date:  2009-10-07       Impact factor: 6.354

Review 5.  Transcriptome complexity in cardiac development and diseases--an expanding universe between genome and phenome.

Authors:  Chen Gao; Yibin Wang
Journal:  Circ J       Date:  2014-04-22       Impact factor: 2.993

Review 6.  The role of CELF proteins in neurological disorders.

Authors:  Jean-Marc Gallo; Carl Spickett
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

7.  Functional requirements of AID's higher order structures and their interaction with RNA-binding proteins.

Authors:  Samiran Mondal; Nasim A Begum; Wenjun Hu; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

Review 8.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

9.  Changes in brain MicroRNAs contribute to cholinergic stress reactions.

Authors:  Ari Meerson; Luisa Cacheaux; Ki Ann Goosens; Robert M Sapolsky; Hermona Soreq; Daniela Kaufer
Journal:  J Mol Neurosci       Date:  2009-08-27       Impact factor: 3.444

10.  MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1.

Authors:  Yoshihiro Kino; Chika Washizu; Yoko Oma; Hayato Onishi; Yuriko Nezu; Noboru Sasagawa; Nobuyuki Nukina; Shoichi Ishiura
Journal:  Nucleic Acids Res       Date:  2009-08-31       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.